dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Filippi, Massimo |
dc.contributor.author | Danesi, Romano |
dc.contributor.author | Derfuss, Tobias |
dc.contributor.author | Duddy, Martin |
dc.contributor.author | Gallo, Paolo |
dc.contributor.author | Tintore Subirana, Mar |
dc.contributor.author | Gold, Ralf |
dc.date.accessioned | 2022-07-19T10:31:18Z |
dc.date.available | 2022-07-19T10:31:18Z |
dc.date.copyright | 2021 |
dc.date.issued | 2022-03 |
dc.identifier.citation | Filippi M, Danesi R, Derfuss T, Duddy M, Gallo P, Gold R, et al. Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis. J Neurol. 2022 Mar;269:1670–7. |
dc.identifier.issn | 1432-1459 |
dc.identifier.uri | https://hdl.handle.net/11351/7821 |
dc.description | Sistema d'atenció de la salut; Esclerosi múltiple; Farmacoeconomia |
dc.description.sponsorship | Novartis facilitated two advisory boards on ‘Unrestricted access for RMS therapy and optimal patient outcome’ with physicians, health economists and patient groups to collect insights on the access to MS therapies across Europe as well as on the therapeutic strategy in MS with high efficacy early. These insights contributed to the manuscript content, which was then suggested for publication on a voluntary basis by the experts who wished to be authors. The content is owned and driven by the authors. The Sponsor had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. |
dc.language.iso | eng |
dc.publisher | Springer |
dc.relation.ispartofseries | Journal of Neurology;269 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Esclerosi múltiple - Tractament |
dc.subject.mesh | Multiple Sclerosis |
dc.subject.mesh | /drug therapy |
dc.title | Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1007/s00415-021-10836-8 |
dc.subject.decs | esclerosis múltiple |
dc.subject.decs | /farmacoterapia |
dc.relation.publishversion | https://doi.org/10.1007/s00415-021-10836-8 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Filippi M] Neurology Unit, Neurorehabilitation Unit, Neurophysiology Service, and Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Rafaele Scientifc Institute, 20132 Milan, Italy. Vita-Salute San Rafaele University, Milan, Italy. [Danesi R] University of Pisa, Pisa, Italy. [Derfuss T] University of Basel, Basel, Switzerland. [Duddy M] The Newcastle Upon Tyne Hospitals, Newcastle upon Tyne, UK. [Gallo P] University of Padua, Padua, Italy. [Gold R ] Ruhr-Universität Bochum, Bochum, Germany. [Tintoré M] Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 34626224 |
dc.identifier.wos | 000705679500001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |